↓ Skip to main content

Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma
Published in
Journal for Immunotherapy of Cancer, January 2013
DOI 10.1186/2051-1426-1-19
Pubmed ID
Authors

Hadas Naveh, Lazar Vujanovic, Lisa H Butterfield

Abstract

Human Adenoviral vectors (HAdV) are immunogenic vectors which have been tested in many vaccination and gene therapy settings. Dendritic cells (DC) transduced by genetically engineered HAdV-5 (HAdV-5/DC), are investigational cancer vaccines being tested clinically. We have previously examined immune responses to HAdV-5 -encoded melanoma tumor antigens. Here, we determined whether the HAdV-5/DC also present immunogenic HAdV-5 vector-derived antigens, and characterized the cellular immune response to the viral as well as encoded melanoma tumor antigens. Both CD4(+) and CD8(+) HAdV-5-specific T cell responses were examined in vitro, with cells from both 8 healthy donors (HD) and 2 melanoma patients. PBMC were stimulated weekly with HAdV-5/DC and responses were examined after each stimulation. We also tested HAdV-5 neutralizing antibody levels and natural killer (NK) cell and regulatory T cell (Treg) activation and expansion in vitro. HAdV-5/DC rapidly induced a high frequency of type 1 cytokine producing HAdV-5-specific CD8(+) and CD4(+) T cells. IFNγ and TNFα-producing T cells predominate. Those with pre-existing cellular memory to HAdV-5 had more robust responses to the HAdV-5 as well as tumor-associated antigens. NK cells are activated while Treg are only minimally and transiently expanded. This study demonstrates that HAdV-5/DC promote strong type I cellular immunity to viral vector-derived antigens as well as to the encoded tumor antigens. The cytokine and chemokine milieu produced by HAdV-5/DC and the activated HAdV-5-specific T cells may enhance responses to encoded tumor antigens as well. These properties make HAdV-5/DC a cancer vaccine capable of activating type 1 virus and tumor antigen-specific immunity in a cooperative way.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 1 7%
Unknown 13 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 43%
Student > Ph. D. Student 4 29%
Student > Master 1 7%
Other 1 7%
Student > Bachelor 1 7%
Other 1 7%
Readers by discipline Count As %
Agricultural and Biological Sciences 4 29%
Immunology and Microbiology 3 21%
Biochemistry, Genetics and Molecular Biology 3 21%
Medicine and Dentistry 2 14%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Other 1 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 June 2018.
All research outputs
#10,455,923
of 13,116,247 outputs
Outputs from Journal for Immunotherapy of Cancer
#667
of 725 outputs
Outputs of similar age
#186,061
of 267,615 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 13,116,247 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 725 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.6. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,615 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them